Morningstar | Fisher & Paykel Remains a Distant Third in Obstructive Sleep Apnoea
Fisher & Paykel Healthcare's treatments for respiratory and acute care (through its hospital division) and obstructive sleep apnoea (as part of its homecare business) possess solid growth prospects. We estimate the overall market opportunity at close to 130 million patients, split equally between the two segments, with an estimated 20 million-25 million patients currently undergoing treatment for these disorders. Hospital in particular enjoys strong competitive advantages because of the dominant market share and high switching costs, which act as barriers to entry and give Fisher & Paykel a narrow moat. In homecare, the transition to home sleep testing will likely boost industry growth rates as more patients undergo treatment compared with conventional sleep labs. However, our valuations remain susceptible to fluctuations in both NZ dollar/U.S. dollar and NZ dollar/euro exchange rates.Fisher & Paykel Healthcare, together with its subsidiaries, is a designer, manufacturer and marketer of medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea (OSA). Co.'s respiratory and acute care products include heated humidifier and respiratory products that are used in the treatment of a variety of medical conditions which interfere with normal respiration. Co.'s OSA products include the continuous positive airway pressure (CPAP) therapy devices, which is used in the treatment of OSA. CPAP is delivered through a mask attached to a flow generator device which generates airflow and enough pressure to keep the airway open.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.